Once-Daily Simeprevir (TMC435) With Pegylated Interferon and Ribavirin in Treatment-Naïve Genotype 1 Hepatitis C: The Randomized PILLAR Study

The phase IIb, double-blind, placebo-controlled PILLAR trial investigated the efficacy and safety of two different simeprevir (SMV) doses administered once-daily (QD) with pegylated interferon (Peg-IFN)-α-2a and ribavirin (RBV) in treatment-naïve patients with HCV genotype 1 infection. Patients were...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Fried, Michael W., Buti, Maria, Dore, Gregory J., Flisiak, Robert, Ferenci, Peter, Jacobson, Ira, Marcellin, Patrick, Manns, Michael, Nikitin, Igor, Poordad, Fred, Sherman, Morris, Zeuzem, Stefan, Scott, Jane, Gilles, Leen, Lenz, Oliver, Peeters, Monika, Sekar, Vanitha, De Smedt, Goedele, Beumont-Mauviel, Maria
Formato: Artigo
Idioma:Inglês
Publicado em: 2013
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4112500/
https://ncbi.nlm.nih.gov/pubmed/23907700
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/hep.26641
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados